-
Posted by
Two Blokes May 4 -
Filed in
Stock
-
3 views
I favor biotech stocks trading below cash value after setbacks; Arvinas (ARVN) fits this description, dropping 25% on Thursday after ending two Phase 3 trials. ARVN's net cash per share is over $12, presenting a 70% upside from its current $7 stock price. ARVN's remaining pipeline holds minimal value; the investment thesis hinges on its substantial cash reserves and potential for activist shareholder intervention.
